Similar companies
| Company | Transaction Value | |
|---|---|---|
 |
OcugenOCGN |
-$4.6M |
 |
AmarinAMRN |
$1.7M |
 |
Gilead SciencesGILD |
-$254M |
 |
Anavex Life SciencesAVXL |
-$14M |
 |
Inovio PharmaceuticalsINO |
-$2.2M |
Insider Transactions
| Name | Transaction Date | Sold / Bought | Shares | Price | Value |
|---|---|---|---|---|---|
| EcoR1 Capital, LLC | Jan 2, 2025 | Buy | 157,880 | $14.7796 | $2.3M |
| EcoR1 Capital, LLC | Dec 31, 2024 | Buy | 146,501 | $14.5695 | $2.1M |
| EcoR1 Capital, LLC | Dec 30, 2024 | Buy | 58,988 | $14.4661 | $850,000 |
| EcoR1 Capital, LLC | Dec 27, 2024 | Buy | 101,659 | $14.4914 | $1.5M |
| EcoR1 Capital, LLC | Dec 26, 2024 | Buy | 16,692 | $14.3804 | $240,000 |
| EcoR1 Capital, LLC | Dec 24, 2024 | Buy | 11,958 | $14.1241 | $170,000 |
| EcoR1 Capital, LLC | Dec 23, 2024 | Buy | 251,502 | $14.2508 | $3.6M |
| EcoR1 Capital, LLC | Dec 20, 2024 | Buy | 704,488 | $14.0776 | $9.9M |
| EcoR1 Capital, LLC | Dec 19, 2024 | Buy | 298,818 | $13.5289 | $4M |
| Galbraith Kenneth | Jan 8, 2024 | Sell | 5,706 | $11.2156 | $64,000 |
| Astle Christopher | Jan 8, 2024 | Sell | 1,431 | $11.2156 | $16,000 |
| Moore Paul Andrew | Jan 8, 2024 | Sell | 2,339 | $11.2156 | $26,000 |
| Galbraith Kenneth | Jan 5, 2024 | Sell | 18,198 | $10.6522 | $190,000 |
| Astle Christopher | Jan 5, 2024 | Sell | 4,563 | $10.6522 | $49,000 |
| Moore Paul Andrew | Jan 5, 2024 | Sell | 7,460 | $10.6522 | $79,000 |
| EcoR1 Capital, LLC | Dec 26, 2023 | Buy | 5,086,521 | $9.8299 | $50M |
| EcoR1 Capital, LLC | Dec 26, 2023 | Buy | 5,086,521 | $9.8299 | $50M |
| Astle Christopher | Dec 11, 2023 | Sell | 886 | $9.1301 | $8,100 |
| EcoR1 Capital, LLC | Jun 16, 2023 | Buy | 3,350,000 | $8.12 | $27M |
| EcoR1 Capital, LLC | Mar 28, 2023 | Buy | 200,000 | $8 | $1.6M |
| Klompas Neil A | Mar 10, 2023 | Sell | 2,977 | $7.8259 | $23,000 |
| EcoR1 Capital, LLC | Jan 20, 2023 | Buy | 163,400 | $9.8843 | $1.6M |
| EcoR1 Capital, LLC | Jan 19, 2023 | Buy | 144,100 | $9.4909 | $1.4M |
| EcoR1 Capital, LLC | Jan 18, 2023 | Buy | 203,000 | $9.9953 | $2M |
| EcoR1 Capital, LLC | Jan 17, 2023 | Buy | 440,000 | $9.8042 | $4.3M |
| EcoR1 Capital, LLC | Jan 13, 2023 | Buy | 342,100 | $9.806 | $3.4M |
| EcoR1 Capital, LLC | Jan 11, 2023 | Buy | 106,300 | $7.8731 | $840,000 |
| EcoR1 Capital, LLC | Jan 10, 2023 | Buy | 920,000 | $7.6491 | $7M |
What's the latest insider transaction for Zymeworks?
The most recent insider transaction for Zymeworks was conducted by EcoR1 Capital, LLC, who sold 157,880 shares on January 2, 2025 at a price of $14.78 per share.
Which insider bought the most ZYME stock over the last two years?
EcoR1 Capital, LLC has bought the most ZYME stock in the last 2 years, with a total value of $174M.
Which insider has sold the most ZYME stock over the last two years?
Galbraith Kenneth has sold the most ZYME stock in the last 2 years, with a total value of $260,000.
What is the total value of insider transactions for Zymeworks (ZYME) in the last 2 years?
According to our estimates, the total value of insider transactions for Zymeworks in the last 2 years is positive, amounting to $174M. This indicates that insiders have predominantly bought shares, showcasing their confidence in the company's future prospects.
How do insider transactions over the last 2 years reflect on Zymeworks' market confidence?
Over the last 2 years, insider transactions for Zymeworks have predominantly involved purchasing shares, indicating a strong confidence among insiders in the company's future prospects. This trend of more purchases than sales could be a positive signal to potential investors about the insiders' view on the company's valuation and growth potential.
Why is monitoring insider trading activity important for investors?
Monitoring insider trading activity is important because it provides insights into the confidence levels of a company's insiders, such as executives and directors, regarding the company's future prospects. Insider buying can signal optimism, suggesting the stock may be undervalued, while insider selling might raise questions about the stock's upcoming performance. However, it's essential to consider that sales can also occur for personal financial reasons. Insider trading activity is a valuable indicator that, when combined with other data, can help inform investment decisions.
